Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Shumway, M. Articles by Beller, J. Search for Related Content PubMed Citation Articles by Shumway, M. Articles by Beller, J. Chronically Mentally Ill Patients Patient Satisfaction, Quality of Life Health Policy and Legislation Other Health Services Issues Schizophrenia Spectrum Disorders

Preferences for Schizophrenia Treatment Outcomes Among Public Policy Makers, Consumers, Families, and Providers

OBJECTIVE: This study measured state public policy makers' ratings of the importance of several key schizophrenia treatment outcomes and compared them with the ratings of primary stakeholders in schizophrenia treatment. METHODS: Three groups of policy makers (40 administrative decision makers, 40 state legislators, and 20 legislative aides) and three groups of core stakeholders (20 persons with schizophrenia, 13 of their family members, and 20 of their mental health care providers) were recruited in Florida. Participants rated 12 descriptions of schizophrenia-related health states that reflected better and worse outcomes in six domains: psychotic symptoms, deficit symptoms, medication side effects, productive activity, daily activity, and social activity. RESULTS: All participants valued functional outcomes, such as improved productive and social activity, more than they valued improvements in symptoms. Public policy makers and primary stakeholders differed in the value they placed on two of the six outcomes. Compared with primary stakeholders, policy makers valued improvements in social functioning significantly more and improvements in medication side effects significantly less. CONCLUSIONS: Policy makers and primary stakeholders place similar value on some of the major goals of schizophrenia treatment, with both groups valuing functional outcomes most highly. However, the difference between groups in the importance placed on medication side effects may lead to conflicts in the allocation of resources to the provision of newer and more expensive medications, which are associated with fewer side effects. This initial examination of policy makers' views provides a starting point for developing consensus about schizophrenia treatment policies.

This article has been cited by other articles:

				T. Calton, M. Ferriter, N. Huband, and H. Spandler A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With Schizophrenia Schizophr Bull, January 1, 2008; 34(1): 181 - 192. [Abstract] [Full Text] [PDF]

				A. S. Bellack Scientific and Consumer Models of Recovery in Schizophrenia: Concordance, Contrasts, and Implications Schizophr Bull, July 1, 2006; 32(3): 432 - 442. [Abstract] [Full Text] [PDF]

				J. R. Bola Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders Research on Social Work Practice, May 1, 2006; 16(3): 263 - 275. [Abstract] [PDF]

				M. E. Foti, S. J. Bartels, A. D. Van Citters, M. P. Merriman, and K. E. Fletcher End-of-Life Treatment Preferences of Persons With Serious Mental Illness Psychiatr Serv, May 1, 2005; 56(5): 585 - 591. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us